Efgartigimod versus intravenous immunoglobulin for antibody-positive autoimmune encephalitis: a retrospective study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Objective To compare the efficacy and safety of efgartigimod and intravenous immunoglobulin (IVIG) in patients with antibody-positive autoimmune encephalitis (AE). Methods This retrospective study included 31 patients with AE, all of whom were antibody-positive, treated between May 2022 and April 2026, with 12 the median number of administrations was 2 (range, 1–6) and 19 in the IVIG group. Short-term outcomes included time to symptom improvement, length of hospital stay, modified Rankin Scale (mRS) score at 3 months, and reduction in mRS score from baseline to 3 months. Longer-term mRS outcomes at 6 months, 12 months, and the last follow-up were exploratory and were analyzed using available assessments. Relapse and adverse events were also compared between the two groups. Results Baseline characteristics were comparable between the two groups. No significant between-group differences were observed in time to symptom improvement, length of hospital stay, 3-month mRS score, or reduction in mRS score from baseline to 3 months (all P > 0.05). In exploratory analyses, mRS scores were numerically lower in the efgartigimod group at 6 months (0.5 vs. 1.0, P = 0.012) and 12 months (0.0 vs. 1.0, P = 0.004), and the distribution of mRS scores at the last follow-up also differed between the groups (P = 0.019); however, these analyses were based on very few patients, and a higher proportion of patients in the efgartigimod group received sequential immunotherapy. These differences therefore cannot be attributed to efgartigimod itself or regarded as evidence of superior long-term efficacy. Relapse rates (16.7% vs. 0%, P = 0.142) and adverse-event rates (16.7% vs. 10.5%, P = 0.630) did not differ significantly between the groups. Conclusion Efgartigimod appears clinically feasible for antibody-positive AE, with short-term efficacy and safety comparable to those of IVIG. Although exploratory analyses showed numerically lower mRS scores in the efgartigimod group at 6 and 12 months, these findings were based on very few patients and were confounded by the imbalance in sequential immunotherapy; they therefore do not demonstrate superior long-term efficacy. These findings require confirmation in prospective controlled studies.
Source: Frontiers in Immunology
Authors: Qingcheng Huang, Xufeng Wang, Min Deng, Tao Li
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7226025848
